Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
View/Open
Author
Barreiro, Antonio
Prenafeta, Antoni
Bech-Sabat, Gregori
Roca, Mercè
Perozo Mur, Eva
March, Ricard
González-González, Luis
Madrenas, Laia
Corominas, Júlia
Fernández, Alex
Moros, Alexandra
Cañete, Manuel
Molas, Merce
Pentinat-Pelegrin, Thais
Panosa, Clara
Moreno, Alberto
Puigvert Molas, Ester
Pol Vilarrassa, Eva
Palmada, Jordi
Garriga, Carme
Prat Cabañas, Teresa
Iglesias-Fernández, Javier
Roca, Núria
Pérez, Mònica
Pradenas, Edwards
Marfil, Silvia
Trinité, Benjamin
Ortiz, Raquel
Clotet, Bonaventura
Blanco, Julià
Díaz Pedroza, Jorge
Ampudia Carrasco, Rosa
Rosales Salgado, Yaiza
Loubat-Casanovas, Jordina
Capdevila Larripa, Sara
Garcia Prado, Julia
Barretina, Jordi
Sisteré-Oró, Marta
Cebollada Rica, Paula
Meyerhans, Andreas
Ferrer, Laura
Publication date
2023-02-02ISSN
2589-0042
Abstract
Current COVID-19 vaccines have been associated with a decline in infection rates,
prevention of severe disease, and a decrease in mortality rates. However, SARSCoV-2 variants are continuously evolving, and development of new accessible
COVID-19 vaccines is essential to mitigate the pandemic. Here, we present
data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer
comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA
adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in
BALB/c and K18-hACE2 mice induced a CD4+ and CD8+ T cell response and
RBD-binding antibodies with neutralizing activity against several variants, and
also showed a good tolerability profile. Significantly, RBD fusion heterodimer
vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in
lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.
Document Type
Article
Document version
Published version
Language
English
Subject (CDU)
619 - Veterinary science
Pages
30
Publisher
Cell Press
Is part of
iScience
Citation
Barreiro, Antonio, Antoni Prenafeta, G. Bech-Sàbat, María J. Roca, Eva Perozo Mur, Ricard March, Luis González-González, et al. 2023. “Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-COV-2”. iScience 26 (3): 106126. https://doi.org/10.1016/j.isci.2023.106126.
Grant agreement number
CDTI/ /IDI-20210115/ES/ /
Program
Sanitat Animal
This item appears in the following Collection(s)
- ARTICLES CIENTÍFICS [2555]
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/